EP1242049A4 - Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i - Google Patents

Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i

Info

Publication number
EP1242049A4
EP1242049A4 EP00986510A EP00986510A EP1242049A4 EP 1242049 A4 EP1242049 A4 EP 1242049A4 EP 00986510 A EP00986510 A EP 00986510A EP 00986510 A EP00986510 A EP 00986510A EP 1242049 A4 EP1242049 A4 EP 1242049A4
Authority
EP
European Patent Office
Prior art keywords
associated antigen
hla class
tumor associated
vaccine compositions
antigen peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00986510A
Other languages
German (de)
English (en)
Other versions
EP1242049A1 (fr
Inventor
John Fikes
Alessandro Sette
John Sidney
Scott Southwood
Esteban Celis
Elissa Keogh
Robert Chesnut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/543,608 external-priority patent/US6602510B1/en
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1242049A1 publication Critical patent/EP1242049A1/fr
Publication of EP1242049A4 publication Critical patent/EP1242049A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
EP00986510A 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i Withdrawn EP1242049A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US543608 1983-10-20
US17044899P 1999-12-13 1999-12-13
US170448P 1999-12-13
US09/543,608 US6602510B1 (en) 2000-04-05 2000-04-05 HLA class I A2 tumor associated antigen peptides and vaccine compositions
US58320000A 2000-05-30 2000-05-30
US583200 2000-05-30
PCT/US2000/034318 WO2001041741A1 (fr) 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i

Publications (2)

Publication Number Publication Date
EP1242049A1 EP1242049A1 (fr) 2002-09-25
EP1242049A4 true EP1242049A4 (fr) 2005-01-05

Family

ID=27389823

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00986510A Withdrawn EP1242049A4 (fr) 1999-12-13 2000-12-13 Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i

Country Status (5)

Country Link
EP (1) EP1242049A4 (fr)
JP (1) JP2003516344A (fr)
AU (1) AU2273701A (fr)
CA (1) CA2393730A1 (fr)
WO (1) WO2001041741A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020616A1 (fr) * 2000-09-01 2002-03-14 Epimmune Inc. Peptides de fixation de hla-a2.1 et leurs utilisations
EP1903056A3 (fr) * 2002-12-10 2008-05-07 Idm Pharma, Inc. Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant
WO2004052917A2 (fr) * 2002-12-10 2004-06-24 Epimmune Inc. Peptides diriges contre des antigenes associes aux tumeurs hla-a1, a2 -a3,-a24,-b7,and -b44 et compositions
WO2004052930A2 (fr) * 2002-12-11 2004-06-24 Pharmexa A/S Epitopes uniques de ciblage
EP1620456B1 (fr) * 2003-04-18 2014-02-26 Biotech Synergy, Inc. Peptides antigenes hla-a2 associes a une tumeur et compositions
JP5015601B2 (ja) 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
EP2084267B1 (fr) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Vaccins comprenant des antigenes de cellules souches cancereuses et procedes
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
EP3085707B1 (fr) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Peptides de liaison hla-dr et leurs utilisations
US9068020B2 (en) 2008-09-02 2015-06-30 Cedars-Sinai Medical Center CD133 epitopes
EP2391635B1 (fr) * 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
RU2600798C2 (ru) * 2009-04-01 2016-10-27 Юниверсити Оф Майами Композиции вакцин и способы их применения
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
IN2014CH00395A (fr) * 2013-02-05 2015-04-03 Nitto Denko Corp
CA2840959A1 (fr) * 2013-02-05 2014-08-05 Nitto Denko Corporation Composition de vaccin
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
EP2966092A4 (fr) 2013-03-08 2016-11-16 Taiho Pharmaceutical Co Ltd Nouveau peptide portant 5 épitopes de ctl liés
CA2919835A1 (fr) 2013-07-31 2015-02-05 Board Of Trustees Of The University Of Arkansas Compositions et methodes permettant de traiter et de prevenir le cancer par ciblage des antigenes glucidiques associes a la tumeur
TWI651094B (zh) 2013-10-21 2019-02-21 日商大鵬藥品工業股份有限公司 新穎ｃｔｌ抗原決定部位４連結肽
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
EP3615574A4 (fr) 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. Constructions reconnaissant spécifiquement le glypicane 3 et utilisations de ces dernieres

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703783B1 (fr) * 1993-03-05 2010-05-05 Epimmune Inc. Procédés pour préparer de peptides immunogènes se liant a hla-a2.1
WO1998033888A1 (fr) * 1997-01-31 1998-08-06 Epimmune, Inc. Cellules a peptides ou a antigenes charges de peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP1242049A1 (fr) 2002-09-25
CA2393730A1 (fr) 2001-06-14
JP2003516344A (ja) 2003-05-13
WO2001041741A1 (fr) 2001-06-14
AU2273701A (en) 2001-06-18
WO2001041741A9 (fr) 2002-05-30

Similar Documents

Publication Publication Date Title
EP1242049A4 (fr) Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i
EP1620456A4 (fr) Peptides antigenes hla-a2 associes a une tumeur et compositions
DK1210113T3 (da) Kombinerede vaccinepræparater
PT1150712E (pt) Formulações para a vacina do vírus do papiloma humano
NL300415I1 (nl) Vaccin tegen antigenen van bacteriën
IL125608A0 (en) Tumor associated antigen peptides and use of same as anti-tumor vaccines
LU91326I2 (fr) Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
PL392363A1 (pl) Kompozycja szczepionki
IL148247A (en) Vaccine and its uses
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
IL131212A0 (en) Recombinant virus and live-virus vaccines
AU2002243314A1 (en) Immunogenic cancer peptides and uses thereof
HK1051544A1 (en) Novel hev antigenic peptide and methods
HUP0202770A3 (en) Human papilloma virus vaccine
EP1316560A4 (fr) Nouvel antigene de type cancer-testis humain et gene de ce dernier
AU5913801A (en) Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
NO996412D0 (no) Antigene peptider
GB9921242D0 (en) Cancer vaccine and diagnosis
HK1047116A1 (zh) 來自mage的免疫原性肽及其應用
GB9911825D0 (en) New vaccine formulations
GB9911824D0 (en) New vaccine formulations
IL141093A0 (en) Tumor associated antigen peptides and use of same as anti-tumor vaccines
GB9910537D0 (en) Therapeutic antibody, Immunogenic compositions and uses
GB9930455D0 (en) Vaccine compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020711

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041119

17Q First examination report despatched

Effective date: 20070823

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080304